Basel, February 13, 2026 – Novartis today announced final results from the Phase III ALIGN study supporting a slowing decline…
PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed as treatment options for emergent and unmet medical…
PRESS RELEASE 02/06/2025, 10:00 CEST Biocartis Announces IVDR Class C CDx Certification of the Idylla™ EGFR Mutation Test Mechelen, Belgium,…